TY - JOUR
T1 - Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy
AU - Kawahara, Takashi
AU - Fukui, Sachi
AU - Sakamaki, Kentaro
AU - Ito, Yusuke
AU - Ito, Hiroki
AU - Kobayashi, Naohito
AU - Izumi, Koji
AU - Yokomizo, Yumiko
AU - Miyoshi, Yasuhide
AU - Makiyama, Kazuhide
AU - Nakaigawa, Noboru
AU - Yamanaka, Takeharu
AU - Yao, Masahiro
AU - Miyamoto, Hiroshi
AU - Uemura, Hiroji
PY - 2015
Y1 - 2015
N2 - Neutrophil-to-lymphocyte ratio (NLR), a simple marker of systemic inflammatory response, has been demonstrated as an independent prognosticator for some solid malignancies, including prostate cancer. In the present study, we evaluated the role of NLR in men who underwent prostate needle biopsy for their initial diagnosis of prostatic carcinoma. Both complete blood counts and free/total (F/T) prostate-specific antigen (PSA) ratio were examined in a total of 3,011 men in our institution. Of these, 1,207 had a PSA level between 4 and 10 ng/mL, and 357 of 810 who subsequently underwent prostate needle biopsy were found to have prostatic adenocarcinoma. NLR value was significantly higher in men with PSA of ≥ 20 ng/mL than in those with PSA of < 20 ng/mL (p < 0.001). NLR was also significantly higher in men with positive biopsy than in those with negative biopsy (p < 0.001). Using NLR cut-off point of 2.40 determined by the AUROC curve, positive/negative predictive values of NLR alone and NLR combined with F/T PSA ratio (cut-off: 0.15) were 56.6%/60.8% and 80.7%/60.1%, respectively. Multivariate analysis revealed that not only F/T PSA ratio (HR = 3.13) but also NLR (HR = 2.21) was an independent risk factor for prostate cancer. NLR is thus likely elevated in patients with prostate cancer. Accordingly, NLR, with or without combination with F/T PSA ratio, may function as a new biomarker to predict prostate cancer in men undergoing prostate needle biopsy.
AB - Neutrophil-to-lymphocyte ratio (NLR), a simple marker of systemic inflammatory response, has been demonstrated as an independent prognosticator for some solid malignancies, including prostate cancer. In the present study, we evaluated the role of NLR in men who underwent prostate needle biopsy for their initial diagnosis of prostatic carcinoma. Both complete blood counts and free/total (F/T) prostate-specific antigen (PSA) ratio were examined in a total of 3,011 men in our institution. Of these, 1,207 had a PSA level between 4 and 10 ng/mL, and 357 of 810 who subsequently underwent prostate needle biopsy were found to have prostatic adenocarcinoma. NLR value was significantly higher in men with PSA of ≥ 20 ng/mL than in those with PSA of < 20 ng/mL (p < 0.001). NLR was also significantly higher in men with positive biopsy than in those with negative biopsy (p < 0.001). Using NLR cut-off point of 2.40 determined by the AUROC curve, positive/negative predictive values of NLR alone and NLR combined with F/T PSA ratio (cut-off: 0.15) were 56.6%/60.8% and 80.7%/60.1%, respectively. Multivariate analysis revealed that not only F/T PSA ratio (HR = 3.13) but also NLR (HR = 2.21) was an independent risk factor for prostate cancer. NLR is thus likely elevated in patients with prostate cancer. Accordingly, NLR, with or without combination with F/T PSA ratio, may function as a new biomarker to predict prostate cancer in men undergoing prostate needle biopsy.
KW - Biomarker
KW - Clinical Section
KW - Neutrophil-to-lymphocyte ratio
KW - Prostate cancer
KW - Prostate needle biopsy
UR - http://www.scopus.com/inward/record.url?scp=84945584132&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945584132&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.5081
DO - 10.18632/oncotarget.5081
M3 - Article
C2 - 26359354
AN - SCOPUS:84945584132
SN - 1949-2553
VL - 6
SP - 32169
EP - 32176
JO - Oncotarget
JF - Oncotarget
IS - 31
ER -